Novartis reported 201M in Interest Expense on Debt for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbvie ABBV:US $ 548M 32M
Alcon AG ALC:SW 29M 1000K
Amgen AMGN:US $ 295M 40M
Biogen BIIB:US $ 66.1M 0.2M
Bristol Myers Squibb BMY:US $ 326M 3M
Eli Lilly And LLY:US $ 84.9M 3.5M
Fresenius Medical Care FME:GR € 83.21M 11.86M
Genmab GEN:DC 4M 1000K
Gilead Sciences GILD:US $ 238M 0M
GRIFOLS GRF:SM € 52.4M 0.33M
Johnson & Johnson JNJ:US $ 10M 50M
Lonza Group LONN:SW 26M 3M
Merk MRK:US $ 243M 34M
Novartis NOVN:VX 201M 5M
Novartis NVS:US $ 201M 5M
Pfizer PFE:US $ 322M 6M
Recordati REC:IM 4.17M 53K
Regeneron Pharmaceuticals REGN:US $ 13.6M 0.5M